Skip to main content

Advertisement

SpringerLink
Log in

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stopeck AT, Fizazi K, Body JJ, et al. (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455. doi:10.1007/s00520-015-2904-5

    Article  PubMed  PubMed Central  Google Scholar 

  2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi:10.1200/JCO.2010.29.7101

    Article  CAS  PubMed  Google Scholar 

  3. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822. doi:10.1016/S0140-6736(10)62344-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587

    Article  PubMed  Google Scholar 

  5. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952

    Article  CAS  PubMed  Google Scholar 

  6. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2008) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. the experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. doi:10.1093/annonc/mdn526

    Article  PubMed  Google Scholar 

  7. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362. doi:10.1200/JCO.2009.21.9584

    Article  CAS  PubMed  Google Scholar 

  8. Bozas G, Allgar V, Greenwood G, et al (2011). Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid (abstract e15116). J Clin Oncol. Available at: http://meetinglibrary.asco.org/content/82466-102.

  9. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F (2013) Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 71:1532–1540. doi:10.1016/j.joms.2013.03.019

    Article  PubMed  Google Scholar 

  10. Saad F, Brown JE, Poznak CV, et al. (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347. doi:10.1093/annonc/mdr435

    Article  CAS  PubMed  Google Scholar 

  11. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369–376

    Article  Google Scholar 

  12. Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66:1516–1517. doi:10.1016/j.joms.2008.02.012

    Article  PubMed  Google Scholar 

  13. Ruggiero SL, Dodson TB, Assael LA, et al. (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(suppl 1):2–12

    PubMed  Google Scholar 

  14. Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67:2698–2699. doi:10.1016/j.joms.2009.07.097

    Article  PubMed  Google Scholar 

  15. Otto S, Marx RE, Tröltzsch M, Ristow O, Ziebart T, Al-Nawas B, Groetz KA, Ehrenfeld M, Mercadante V, Porter S, Bedogni A, Campisi G, Fusco V, Dayisoylu E, Fliefel R, Herlofson BB, Pautke C, Kwon T-G, Fedele S (2015) Comments on “Diagnosis and Management of Osteonecrosis of the Jaw: a systematic review and international consensus”. J Bone Miner Res 30:1113–1115. doi:10.1002/jbmr.2525

    Article  PubMed  Google Scholar 

  16. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—20 14 update. J Oral Maxillofac Surg 72:1938–1956. doi:10.1016/j.joms.2014.04.031

    Article  PubMed  Google Scholar 

  17. Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O (2011) Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol 29(17):521–522. doi:10.1200/JCO.2011.35.1551 Epub 2011 May 2

    Article  Google Scholar 

  18. Setabutr D, Hales NW, Krempl GA (2010) Necrotizing fasciitis secondary to bisphosphonate-induced osteonecrosis of the jaw. Am J Otolaryngol 31:127–129. doi:10.1016/j.amjoto.2008.11.002

    Article  PubMed  Google Scholar 

  19. Kaehling C, Streckbein P, Schmermund D, Henrich M, Burchert D, Gattenloehner S, Howaldt HP, Wilbrand JF (2014) Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg 42:1203–1206. doi:10.1016/j.jcms.2014.02.009

    Article  PubMed  Google Scholar 

  20. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057

    Article  CAS  PubMed  Google Scholar 

  21. Berenson JR, Hillner BE, Kyle RA, et al. (2002) American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719–3736

    Article  PubMed  Google Scholar 

  22. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047–1053

    Article  CAS  PubMed  Google Scholar 

  23. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K (2007) American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464–2472

    Article  CAS  PubMed  Google Scholar 

  24. Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82:516–517

    Article  PubMed  Google Scholar 

  25. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432

    Article  CAS  PubMed  Google Scholar 

  26. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow BE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Van Roenn JH (2011) American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227. doi:10.1200/JCO.2010.32.5209

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy

    Vittorio Fusco

  2. Unit of Maxillofacial Surgery, Department of Neurosciences – DNS, University of Padua, Padua, Italy

    Alberto Bedogni

  3. Bristol Cancer Institute, University Hospitals Bristol NHS, Bristol, UK

    Alfredo Addeo

  4. Department of Surgical, Oncology and Oral Sciences - Sector of Oral Medicine, Palermo University, Palermo, Italy

    Giuseppina Campisi

Authors
  1. Vittorio Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Bedogni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfredo Addeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppina Campisi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vittorio Fusco.

Ethics declarations

Disclosures

Dr. Fusco has participated in advisory boards on metastatic bone disease (Amgen); he transferred the fee to an advocacy patient group.

Dr. Addeo received expert grant by Bristol-Myers Squibb and Pierre Fabre, and travel and accommodation expenses by Boehringer Ingelheim.

Conflict of interest

The remaining authors have stated that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fusco, V., Bedogni, A., Addeo, A. et al. Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?. Support Care Cancer 25, 345–349 (2017). https://doi.org/10.1007/s00520-016-3147-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-016-3147-9

Keywords

Search

Navigation